Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099328 · ClinicalTrials.gov registry record · NA
Recasting or Book Reading by Parents or Clinicians
A NA study of Developmental Language Disorder and Language Impairment, sponsored by University of Delaware.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT05099328: Recruiting NA study of Developmental Language Disorder and Language Impairment, sponsored by University of Delaware.
NCT05099328 is a NA study of Developmental Language Disorder and Language Impairment that is actively recruiting participants, run by University of Delaware. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05099328, a NA study of Developmental Language Disorder and Language Impairment, is actively recruiting participants, sponsored by University of Delaware.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
Developmental Language Disorder (DLD) affects approximately seven percent of the population and is characterized by grammatical deficits that cascade into lifelong academic challenges and under-employment. Current treatments for DLD produce good outcomes under ideal, high intensity conditions or when parents have been trained to deliver therapy using intense coaching methods; however, current publicly funded service delivery systems and private-pay reimbursement models do not support treatment being delivered in this ideal fashion for children older than three. This project will examine alternative methods of delivering treatment that may be more feasible under typical conditions and will identify implementation barriers, with the goal of improving long-term outcomes for children with DLD. We hypothesize that feasibility and palatability will influence dose, which will in turn affect the overall language outcomes.
Primary Outcome
Children will respond to 20 item elicited production probes that ask the child to produce the treated structures and a control structure. Elicited Production Probes are highly reliable (ICC \>.9), valid measures of children's use of a grammatical form. They have clinical relevance and align with the types of items that occur on standardized tests of language use.
Conditions Studied
Interventions
- BEHAVIORAL Recast Therapy
- BEHAVIORAL Syntax Stories
Study Locations (2)
Delaware
- University of Delaware - Newark
Maryland
- University of Maryland - College Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2027-08-28 |
| Phase | NA |
What NCT05099328 shows while recruiting
NCT05099328 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Developmental Language Disorder and Language Impairment appearing as the primary indexed condition, and to 2 interventions - of which Recast Therapy is the first listed.
NCT05099328 reports a single indexed study location in Delaware, Maryland.
Frequently Asked Questions
What is clinical trial NCT05099328 about?
NCT05099328 is a clinical study titled "Recasting or Book Reading by Parents or Clinicians". Developmental Language Disorder (DLD) affects approximately seven percent of the population and is characterized by grammatical deficits that cascade into lifelong academic challenges and under-employment. Current treatments for DLD produce good outcomes under ideal, high intensity conditions or whe...
What is the current status of trial NCT05099328?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2021-09-28. Estimated completion is 2027-08-28.
What conditions does trial NCT05099328 study?
This clinical trial studies the following conditions: Developmental Language Disorder and Language Impairment.
What interventions are being tested in trial NCT05099328?
The interventions under investigation include: Recast Therapy (BEHAVIORAL), Syntax Stories (BEHAVIORAL).
Who is sponsoring clinical trial NCT05099328?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05099328 being conducted?
This trial has 2 study locations across Delaware, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Developmental Language Disorder and Language Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05099328's enrollment target sits among peer trials
160 628th of 2000 higher than 1,348 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI